Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Drug Formulary Review Archives – March 1, 2006

March 1, 2006

View Archives Issues

  • Sentinel Event Alert: The time for medication reconciliation is now

    By now, hospitals should have fully developed and implemented a process to comply with 2005s National Patient Safety Goal (NPSG) 8 of the Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL: Accurately and completely reconcile medications across the continuum of care.
  • Some whos, hows, whens, and whys of reconciliation

    Medication reconciliation is a requirement of the Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL. Many hospitals, however, still are bogged down in details of developing and implementing this process. A Joint Commission surveyor recently gave some tips on navigating the rough waters.
  • Provide an accurate list for the next level of care

    The last important piece of the medication reconciliation process is for hospitals to provide a list of the patients current (continuing) medications for his or her next level of care.
  • News Briefs

    FDA issues public health advisory for aprotinin injection (Trasylol); FDA revises format of prescription drug information; Current influenza viruses resistant to amantadine, rimandatine; Report: Many CAD patients dont take drugs that could extend lives; ICAP approves uniform labeling guidelines; Serious liver toxicity reported with use of telithromycin (Ketek)
  • In The Pipeline

    Viventia Biotech has announced that the FDA has designated the companys lead drug, Proxinium (formerly known as VB4-845), as a fast-track product for the treatment of patients with recurrent squamous cell carcinoma of the head and neck.
  • Drug Criteria & Outcomes: Exenatide (Byetta) Drug Evaluation

    Exenatide is an incretin mimetic that is similar to the glucagon-like peptide-1(GLP-1) in the body, and acts by binding to GLP-1 receptors. It improves glycemic control by increasing glucose-dependent insulin secretion, improving first-phase insulin response, decreasing glucagon secretion, slowing gastric emptying, and reducing food intake.